A federal grand jury in Salt Lake City returned an indictment against a Utah physician who allegedly received, recommended, delivered, and sold to his unwitting patients, misbranded drugs from China that were not approved by the United States Food and Drug Administration (FDA). According to the allegations in court documents, Justin Bradley Watkins, 39, of Pleasant View, Utah, obtained misbranded drugs from China, specifically peptides that he knew were not FDA approved. Watkins obtained the drugs through a middleman between February 2024 to April 2025. Watkins purchased the peptides at a deeply discounted price, and knew they were not backed by proper, reliable testing and clinical trials. In furtherance of the fraud, Watkins made and affixed labels to vials and/or pill bottles before providing them to clinic staff. None of the labels disclosed the name and place of business of the manufacturer, packer or distributor, as required by the FDA’s Food, Drug, and Cosmetic Act (FDCA). During the fraud period, Watkins recommended, provided, delivered, and sold misbranded, non-FDA-approved peptides to over 200 trusting patients.